Reply




We thank Polasek et al for the opportunity to clarify some crucial points of our study. First, our study is observational and retrospective, thus needing further confirmation by prospective ad hoc studies as stated in the report. Obviously, given the retrospective and observational nature of the study, a control group cannot be expected unless we performed cardiac resynchronization therapy (CRT) device implantation disregarding the guidelines and it is not our case. Accordingly, we just commented on reported results, but we did not discourage CRT implantation in these patients. Second, the hypothesis generated by our data was the existence of an upper cut-off value of QRS duration above which CRT is less effective because of extensive electrical and structural remodeling. Our observations are consistent with findings that showed a worse clinical outcome and prognosis related to either left bundle branch block morphology or prolonged QRS duration in patients with heart failure. A recent large prospective observational study, totaling 3,319 patients with CRT, showed that cardiac mortality was highest at the upper extremes of QRS duration. Moreover, a subanalysis of the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial showed a linear reduction of left ventricular volumes after CRT as the QRS duration increases from 120 to 180 ms, followed by a declining efficacy from 180 ms onward. Third, it is important to underline that we described and commented the results of meta-analysis as usually is done in the discussion section. Furthermore, we deliberately chose to comment on the graph showing the combined end point of death and hospitalization for heart failure, rather than death only, because this is more representative of the efficacy of CRT given the well-established deleterious economic and clinical impact of hospitalization for worsening heart failure. Finally, we would advise Polasek et al that it is hard to discuss unpublished results and compare them with others using different end points: a less validated end point (≥10% reduction of the left ventricular end-systolic diameter) in Polasek data and a well-established end point (≥15% reduction of the left ventricular end-systolic volume) in our study.


References



  1. 1. Sassone B., Gambetti S., Bertini M., Beltrami M., Mascioli G., Bressan S., Fucà G., Pacchioni F., Pedaci M., Michelotti F., Bacchi Reggiani M.L., and Padeletti L.: Relation of QRS duration to response to cardiac resynchronization therapy. Am J Cardiol 2015; 115: pp. 214-219

  2. 2. Shenkman H.J., Pampati V., Khandelwal A.K., McKinnon J., Nori D., Kaatz S., Sandberg K.R., and McCullough P.A.: Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002; 122: pp. 528-534

  3. 3. Baldasseroni S., Opasich C., Gorini M., Lucci D., Marchionni N., Marini M., Campana C., Perini G., Deorsola A., Masotti G., Tavazzi L., and Maggioni A.P.: Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure. Am Heart J 2002; 143: pp. 398-405

  4. 4. Gasparini M., Leclercq C., Yu C.M., Auricchio A., Steinberg J.S., Lamp B., Klersy C., and Leyva F.: Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: a multinational 10-year experience: data from the Multicenter International CRT Study. Am Heart J 2014; 167: pp. 203-209

  5. 5. Gold M.R., Thébault C., Linde C., Abraham W.T., Gerritse B., Ghio S., St. John Sutton M., and Daubert J.C.: Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study. Circulation 2012; 126: pp. 822-829

  6. 6. Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B., Daubert C.J., Sherfesee L., Wells G.A., and Tang A.S.: An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: pp. 3547-3556

  7. 7. Lee W.C., Chavez Y.E., Baker T., and Luce B.R.: Economic burden of heart failure: a summary of recent literature. Heart Lung 2004; 33: pp. 362-371

  8. 8. Kristensen S.L., Jhund P.S., Køber L., Preiss D., Kjekshus J., McKelvie R.S., Zile M.R., Anand I.S., Wikstrand J., Wedel H., Komajda M., Carson P.E., Cleland J.G., and McMurray J.J.: Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail 2015; 17: pp. 169-176

  9. 9. Bertini M., Höke U., van Bommel R.J., Ng A.C., Shanks M., Nucifora G., Auger D., Borleffs C.J., van Rijnsoever E.P., van Erven L., Schalij M.J., Marsan N.A., Bax J.J., and Delgado V.: Impact of clinical and echocardiographic response to cardiac resynchronization therapy on long-term survival. Eur Heart J Cardiovasc Imaging 2013; 14: pp. 774-781

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Effect of Coronary Thrombectomy in Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction
  2. Long-Term Outcome After Ablation of Right Atrial Tachyarrhythmias After the Surgical Repair of Congenital and Acquired Heart Disease
  3. Emergent Cesarean Section in the Catheterization Laboratory for Spontaneous Coronary Artery Dissection
  4. Suboptimal Choice of Methodology for Meta-Analysis and Publication Bias Assessment

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 30, 2016 | Posted by in CARDIOLOGY | Comments Off on Reply

Full access? Get Clinical Tree
Get Clinical Tree app for offline access